BUSINESS● LOW1h ago · Sep 13, 2026, 5:32 PM
Scholar Rock jumps 12% after FDA approves isembyld for spinal muscular atrophy
Seeking Alpha Tech · north america
Scholar Rock's stock increased by 12% following the FDA's approval of its drug, isembyld, for treating spinal muscular atrophy. This approval marks a significant development for the company and for patients with the condition.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS29m agoOur riders earn average of N100k per week – Chowdeck CEO, Femi AlukoVanguard NigeriaBUSINESS43m agoNLCIL hands over four electric vehicles to AurovilleThe Hindu